Sign In
Buy BCDA
$0.87
-0.0256 (-2.84%)
At Close: Jun 03, 2026
Has BioCardia (BCDA) Outpaced Other Medical Stocks This Year?
11:18am, Wednesday, 24'th Aug 2022
Here is how BioCardia, Inc. (BCDA) and Ensign Group (ENSG) have performed compared to their sector so far this year.
BioCardia, Inc. (BCDA) CEO Peter Altman on Q2 2022 Results - Earnings Call Transcript
10:32pm, Wednesday, 10'th Aug 2022
BioCardia, Inc. (NASDAQ:BCDA ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Jules Abraham - IR, CORE IR Peter Altman - President and CEO David McClung - CFO Confere
BioCardia, Inc. (BCDA) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Wednesday, 10'th Aug 2022
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 50% and 412.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022
02:04pm, Thursday, 04'th Aug 2022
SUNNYVALE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia, Inc. (BCDA) Reports Q1 Loss, Lags Revenue Estimates
07:34pm, Wednesday, 11'th May 2022
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -26.67% and 68.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) CEO Peter Altman on Q1 2022 Results - Earnings Call Transcript
06:01pm, Wednesday, 11'th May 2022
BioCardia, Inc. (NASDAQ:BCDA ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Jules Abraham - Investor Relations, CORE IR Peter Altman - President & Chief Executive Offi
BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study
12:03pm, Wednesday, 13'th Apr 2022
BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.
FDA Approves BioCardia's Phase 1 Trial With Cell Therapy In COVID-19, Shares Jump
09:32am, Tuesday, 12'th Apr 2022
The FDA has signed off BioCardia Inc's (NASDAQ: BCDA) Investigational New Drug (IND) application for BCDA-04 to initiate Phase 1/2 trial in adult patients recovering from Acute Respiratory Distress
Top Penny Stocks to Buy? 3 As Stock Futures Climb Before Market Open
09:25am, Tuesday, 12'th Apr 2022
Here's what you need to know about buying penny stocks on April 12th The post Top Penny Stocks to Buy? 3 As Stock Futures Climb Before Market Open appeared first on Penny Stocks to Buy, Picks, News an
BioCardia, Inc. (BCDA) CEO Peter Altman on Q4 2021 Results - Earnings Call Transcript
07:53pm, Tuesday, 29'th Mar 2022
BioCardia, Inc. (BCDA) CEO Peter Altman on Q4 2021 Results - Earnings Call Transcript
BioCardia to Host 2021 Financial Results and Corporate Update Conference Call on March 29, 2022
08:00am, Thursday, 24'th Mar 2022
SUNNYVALE, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
Safety Board Recommends BioCardia''s Heart Failure Cell Therapy To Continue Unchanged
03:29pm, Monday, 14'th Feb 2022 Benzinga
The independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for BioCardia Inc''s (NASDAQ: BCDA ) ongoing Phase 3 CardiAMP Cell Therapy Heart Failure Trial. The DSMB based its review on all available data for the 108 patients enrolled with an additional six crossover patient procedures Full story available on Benzinga.com
Safety Board Recommends BioCardia's Heart Failure Cell Therapy To Continue Unchanged
10:29am, Monday, 14'th Feb 2022
The independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for BioCardia Inc's (NASDAQ: BCDA) ongoing Phase 3 CardiAMP Cell Therapy Heart Failure Trial. The DSM
Doximity, Aptevo top healthcare gainers; Varex Imaging, BioCardia among losers
03:02pm, Wednesday, 09'th Feb 2022 Seeking Alpha
Doximity DOCS +20%. Aptevo Therapeutics APVO +17%. Varex Imaging (VREX) -11%. BioCardia (BCDA) -8%.
Why Are BioCardia Shares Trading Higher Today?
07:53pm, Thursday, 03'rd Feb 2022 Benzinga
The FDA has granted Breakthrough Device Designation for BioCardia Inc''s (NASDAQ: BCDA ) CardiAMP Cell Therapy System to treat heart failure. The company noted that it is believed to be the first cardiac cell therapy to receive FDA Breakthrough Device status. CardiAMP Cell Therapy uses a patient''s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure. Related:
